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Aspirin is widely used to lessen the risks of cardiovascular events. Some studies suggest that patients with multiple
sclerosis have an increased risk for some cardiovascular events, for example, venous thromboembolism and
perhaps ischemic strokes, raising the possibility that aspirin could lessen these increased risks in this population
or subgroups (patients with limited mobility and/or antiphospholipid antibodies). However, aspirin causes a small
increased risk of hemorrhagic stroke, which is a concern as it could potentially worsen a compromised blood-brain
barrier. Aspirin has the potential to ameliorate the disease process in multiple sclerosis (for example, by limiting
some components of inflammation), but aspirin also has the potential to inhibit mitochondrial complex I activity,
which is already reduced in multiple sclerosis. In an experimental setting of a cerebral ischemic lesion, aspirin
promoted the proliferation and/or differentiation of oligodendrocyte precursors, raising the possibility that aspirin
could facilitate remyelination efforts in multiple sclerosis. Other actions by aspirin may lead to small improvements
of some symptoms (for example, lessening fatigue). Here we consider potential benefits and risks of aspirin usage
by patients with multiple sclerosis.
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Multiple sclerosis (MS) is a debilitating chronic disease
characterized by inflammation, demyelination, axonal
transection, and neurodegeneration in the central ner-
vous system (CNS), leading to motor, sensory, and cog-
nitive difficulties [1, 2]. Although MS is thought to have
an autoimmune component, other mechanisms contrib-
ute to disease progression, for example, mitochondrial
dysfunction, activated microglia, and intracerebral vascu-
lar changes [3–6]. Vascular changes include blood-brain
barrier (BBB) leakage [7, 8], areas of decreased or increased
cerebral perfusion [9–13], and vessel occlusion [14–16]. In
line with these vascular changes, some reports have sug-
gested that patients with MS have a greater risk of ischemic
stroke and venous thrombosis [17–23]. These patients
also have a higher incidence of antiphospholipid antibodies
(APLAs), the main feature of antiphospholipid syndrome
(APS); and patients with APS have an elevated risk of ische-
mic stroke and thrombosis.* Correspondence: slevine@kumc.edu
1Department of Molecular and Integrative Physiology, University of Kansas
Medical Center, Kansas City, KS, USA
Full list of author information is available at the end of the article
© 2015 Tsau et al. This is an Open Access artic
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/Aspirin (acetylsalicylic acid, ASA) is a popular and readily
available drug that has a variety of effects including alleviat-
ing pain and reducing fever, and it is often used for the sec-
ondary prevention of cardiovascular events in patients at
risk [24–26]. Given the elevated risks for stroke and venous
thrombosis in MS, ASA may help counter the development
of these conditions [27–29]. ASA may also positively im-
pact other facets of MS disease activity (for example, it may
reduce inflammation, lessen fatigue, and promote remyeli-
nation). However, ASA usage increases the risk for
hemorrhagic stroke [30–32], indicating the possibility that
ASA could worsen BBB disruption in MS. ASA also has
the potential to interfere with mitochondrial complex I ac-
tivity [33], which has reduced activity in MS [34, 35]. Thus,
the risk-to-benefit ratio for ASA usage by MS patients is
unclear. This paper will review the potential benefits
(Table 1) and risks (Table 2) associated with ASA usage in
patients with MS.Cardiovascular risks in MS
Patients with MS may have an increased risk for
cardiovascular disease
Multiple studies have examined the risks for stroke in
patients with MS, but questions remain about thele distributed under the terms of the Creative Commons Attribution License
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Table 1 Potential benefits of ASA usage in MS
Feature Description ASA’s effect
Ischemic stroke MS patients may have an increased risk of stroke
[17, 18, 20, 36, 37].
ASA reduces the risk of ischemic stroke in some subjects, for
example, those who had a previous stroke [24–26, 79]. ASA
decreases platelet activation and aggregation through irreversible
inhibition of platelet COX-1, and the resultant decrease in TXA2
production has a cardioprotective effect [57, 64]. It is unknown
whether the risk of strokes in MS patients will be reduced in
response to ASA.
Thrombosis MS patients have an increased risk of venous
thrombosis [18, 19, 21–23, 39].
ASA lowers the incidence of venous thrombosis in some
subjects, for example, orthopedic surgery patients and those
who experienced an unprovoked venous thromboembolism
[27, 28, 88]. It is not known whether the risk of venous
thrombosis is reduced in response to ASA in MS patients,
but ASA reduces the risk for first thrombosis in patients with
APLAs [107].
A higher percentage of MS patients have
APLAs than controls [96–98]. APLAs are a
diagnostic feature of APS, which involves
thromboses.
Platelets Platelets are activated in MS and have been
implicated in contributing to MS pathogenesis,
such as by promoting inflammation [71, 72, 111].
Anticoagulants decreased the severity of EAE [110, 211]. ASA
lowers one indicator of platelet activation in MS patients.
Fibrin Limiting fibrin formation reduced EAE disease
activity [114, 115]. Fibrin deposition may activate
microglia [113].
ASA may lessen fibrin deposition and induce fibrinolysis [116].
Thrombin Is thought to promote inflammatory disease states
of the CNS [117], and thrombin is associated with
multiple pathological features in EAE [118].
ASA may decrease thrombin at microvascular injury sites [119].
Microglia Activated microglia can have a pro-pathogenic
role in MS [3–5].
ASA may reduce production of proinflammatory cytokines and
reactive oxygen species (ROS) by microglia [155–157].
Inflammation Multiple components of inflammation
(for example, ROS, proinflammatory cytokines)
are thought to contribute to MS pathogenesis.
ASA may promote the resolution of inflammation via the
production of lipoxin A4 [158, 159].
Remyelination Remyelination is incomplete in MS [212]. ASA may increase ciliary neurotrophic factor and promote the
differentiation and proliferation of oligodendrocyte precursors
[161, 163].
Fatigue Fatigue is a common symptom of MS. ASA may reduce fatigue in MS patients via antipyretic effects
or by countering proinflammatory cytokines [164, 176, 177].
Depression Depression is more common in MS than in
the general population [180].
ASA usage may lower the risk for major depression, and some
evidence shows that ASA in combination with fluoxetine
enhances treatment for depression [181, 182, 188]. It is unknown
whether ASA would help to reduce depression in MS, but other
studies suggest that it can have negative impacts or side effects
in depressed patients (see Table 2)
General disease activity MS patients given calcium aspirin (Solprin)
[147, 148] or EAE subjects given sodium salicylate
or ASA [149–152]. Studies were performed
decades ago.
Overall, the outcome is inconclusive. There was no effect in MS
patients [147, 148], but evaluation was done using an outdated
measure of disease activity. In EAE, disease onset was delayed
and/or disease incidence reduced in 3 out of 4 studies
[149, 151, 152]. Treatment after clinical signs appeared resulted
in no benefit [149], and in one study disease severity was
increased although disease onset was delayed [151].
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hospitalized for ischemic stroke (odds ratio (OR): 1.66,
95 % CI = 1.33–2.09) when compared to non-MS con-
trols [36], but there were no differences or elevated risk
for hemorrhagic stroke [36, 37]. A study on 32 different
immune-mediated diseases (including MS) found that
the risk for ischemic stroke was significantly increased
(standardized incidence ratio = 3.05) in the year follow-
ing a hospitalization for MS [37]. A study of 13,963 pa-
tients with MS compared to 66,407 non-MS controls
from the Danish National Registry of Patients [17] alsofound a heightened risk of stroke shortly after MS diag-
nosis (for example, within a year) with the elevated risk
being most pronounced in younger MS patients and ab-
sent in older MS subjects (≥56 years) [17]. However, the
opposite trend for the effect of age on the risk of strokes
in patients with MS was observed in a Swedish study
[18]; complicating the interpretation, it is unclear if the
same types of strokes were evaluated in these studies.
When considering these studies, however, it is important
to recognize that patients who are having an MS relapse
are often misdiagnosed as having a stroke, particularly
Table 2 Potential risks of aspirin usage in MS
Adverse event Description ASA’s mechanism
Cerebral bleeding/hemorrhagic
strokes)
There is an increase in the incidence of intracranial
hemorrhages with antiplatelet treatment [30–32, 79].
Because MS patients can have a compromised BBB [7, 8],
the risk of intracerebral bleeding in MS may be greater
with ASA usage.
Platelets/coagulation may act to limit BBB damage
in MS. ASA’s antiplatelet/anticoagulation properties
potentially increase the likelihood that BBB leakage
could be prolonged or worsened.
Mitochondrial function complex
I inhibition
Mitochondrial complex I activity is reduced in MS [34, 35].
ASA may inhibit complex I [33], and the effect may be
more pronounced with glutathione depletion [140], which
is thought to occur in MS [141, 142]. Inhibition of complex
I may lead to an increase in ROS production [143].
Direct inhibition of complex I by ASA [33].
Increased gastrointestinal
bleeding
ASA treatment has been found to increase the incidence
of gastrointestinal and other extracranial bleeding [31],
and risk increases with patient age [198].
Anticoagulation (antiplatelet); ASA blocks the synthesis
of gastroprotective prostaglandins via inhibition of
COX-1, which increases gastrointestinal bleeding [198].
Increased risk of bleeding with
concurrent use of ASA with an
antidepressant (SSRI)
Both ASA and the antidepressant class selective serotonin
reuptake inhibitors (SSRIs) increase risk of bleeding by
themselves. Following an acute myocardial infarction, the
combination of ASA and SSRI treatment increases the risk
of bleeding in patients compared to ASA alone [191].
Anticoagulation (antiplatelet)
Adverse effects relative to
depression
Concurrent use of ASA with citalopram may lead to an
increased risk of adverse events, such as anxiety, akathesia,
and suicidal behavior [189]. Also, NSAIDs may interfere
with the antidepressant effects of SSRIs, preventing
depressed patients from achieving relief [190].
The mechanism is unknown, but possibly NSAIDs
are blocking the production of a protective mediator,
for example, anti-inflammatory cytokine [189].
Hearing loss and tinnitus Although rare, hearing loss and tinnitus have been
reported with high dosages of salicylate (6–8 g or more
per day) [200, 203, 204]. In men, regular usage of ASA
also has been found to heighten the risk for loss of
hearing, and the effect is more pronounced in younger
individuals [213].
The mechanism is not known, but may be through
suppressing GABAergic inhibition [203, 204]; sodium
salicylate also affects cochlear function [200, 204]
Respiratory attacks, asthma Approximately 10 % [207] to 21 % [206] prevalence of
ASA-induced asthma in adult asthmatic patients and
5 % prevalence in asthmatic children, based on both
retrospective/self-report studies and provocation
studies [206].
COX enzyme inhibition leading to decreased PGE2
and enhanced leukotriene and histamine
production [198, 206, 210].
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showing elevated risks for stroke in patients with MS
may be inaccurate and reflect misdiagnoses or an in-
crease in the surveillance (for example, MRI and more
frequent physician visits) of this patient population iden-
tifying asymptomatic lesions suggestive of strokes [38].
Venous thromboembolism (VTE) appeared to be ele-
vated in patients with MS compared to controls [18, 19,
21–23]. Ocak and colleagues [39] found an increased
risk of venous thrombosis in MS patients: the OR for
venous thrombosis in MS was 2.4 (95 % CI 1.3–4.3), and
the OR increased to 12.5 (95 % CI 1.5-107.9) in patients
with both MS and increased factor VIII levels, which in-
dicates the additional risk factor of thrombophilia. Also,
APLAs, which are a diagnostic feature of APS that re-
sults in thromboses, occur in a greater percentage of MS
patients compared to controls (discussed later in the
subsection “ASA and antiphospholipid antibodies”).
Individuals who have an occupation that involves
prolonged sedentary behavior or patients experiencing
immobilization have an increased risk of venous throm-
bosis compared to more mobile people [39, 40]. Asedentary lifestyle is also associated with an increased
risk of stroke [41]. The activity level of patients with MS
is less than that of healthy control subjects [42]. Physical
inactivity, particularly in patients needing a wheelchair
or who are bedridden, may contribute to the higher
prevalence of thrombosis and ischemic strokes in pa-
tients with MS [43, 44].
Whether patients with MS have an increased risk for
myocardial infarction is unclear [20]. In one study, MS
patients were found to have decreased risks of being
hospitalized for myocardial infarction and ischemic heart
disease [36]; however, a recent study conducted with an
initial cohort of 8,281 MS patients in Sweden deter-
mined that the risks for myocardial infarction, heart fail-
ure, and stroke were increased in individuals with MS
compared to matched controls, and that these risks were
more pronounced in women than men [18]. Shared
pathological factors (for example, inflammation, oxida-
tive stress, thrombogenic factors) between MS and car-
diovascular diseases may explain the association between
these conditions [18]. Of note, MS patients with ≥ 1 car-
diovascular risks had increased MRI indications of
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crease in lesion burden [45].
Treatments for MS may also increase the risk for car-
diovascular diseases [20]. For example, systemic gluco-
corticoids have been reported to increase risks of stroke,
myocardial infarction, and atrial fibrillation [20]. Add-
itionally, a positive association was found for cardiovas-
cular risk factors and the use of disease modifying
therapies (DMTs) such as interferon-β and glatiramer
acetate [46]. For example, about 20 % of MS patients on
DMTs versus about 5 % of MS patients naïve to DMTs
had diastolic blood pressure above 90 mmHg, and about
25 % of MS patients on DMTs versus about 14 % MS
patients naïve to DMTs had glucose > 100 mg/dL [46].
The association was more pronounced in chronic pro-
gressive MS patients compared to relapsing remitting
MS (RRMS) patients, but the correlation to disease ac-
tivity (for example, rate of clinical relapse) was weak
[46]. Although similar studies have not been conducted
for more recent DMTs, cardiac side effects can be asso-
ciated with these agents. For example, an increase in
hypertension has been noted for teriflunomide (4 %
treated versus 2 % placebo [47]). A reduction of heart
rate can occur within six hours of fingolimod initiation
[48], and there can be an increase in blood pressure in a
small percentage of patients over the long term [49].
Increased risk of dying from cardiovascular disease in
patients with MS
Besides a possibly increased risk of cardiovascular dis-
ease (CVD), studies generally suggest that MS patients
have a heightened risk of dying from CVD [43, 50]. As
reviewed in Christiansen [20], patients with MS have a
6–34 % greater risk of death by CVD or stroke than for
the overall population, and greater than 10 % of MS pa-
tients may have stroke as the cause of death. An analysis
of 9,881 MS patients in the Danish Multiple Sclerosis
Registry revealed that the mortality rate from CVD was
significantly higher in MS patients compared to matched
controls [50], and an analysis of over 6,000 patient
deaths in the Danish MS Registry revealed that 17.6 % of
deaths were caused by vascular or cardiac diseases,
which was the most frequently listed cause of death out-
side of MS itself [43]. The standard mortality rate (the
number of subjects who died from the specific cause di-
vided by the number of deaths expected from population
mortality statistics) of cardiac or vascular diseases in this
same patient population was 1.34, indicating about a 34
% greater chance of death by CVD in MS patients when
compared to general population mortality statistics [43].
In contrast, a study in South Wales revealed that while
CVD caused 16 % of deaths in the MS population sur-
veyed, this rate did not differ from the expected death
rates in the general population [51].While it appears that patients with MS have a greater
likelihood of dying from cardiovascular-related issues,
the underlying causative reason is not clear. These pa-
tients may lead a more sedentary lifestyle than healthy
individuals due to motor symptoms and fatigue, for ex-
ample [42], particularly as the disease progresses, and a
less active lifestyle has been associated with cardiovascu-
lar risk factors such as impaired glucose tolerance and
the development of metabolic syndrome in the general
population [52, 53]. Furthermore, altered metabolic re-
sponses in patients with MS, such as increased adipose
lipolytic activity, could be a factor in lower physical per-
formance [54]. Several studies (reviewed in [55]) suggest
that patients with MS are more likely to develop vascu-
lar disease and comorbidities related to metabolic syn-
drome (such as obesity, impaired glucose tolerance, and
dyslipidemia), but these factors may develop or worsen
as a result of progressively debilitating MS symptoms.
Because many of these studies are retrospective, correl-
ational designs, the exact cause and effect relationship
between MS and CVD risk and mortality cannot be eas-
ily discerned. It is unclear whether CVD risk factors
contribute to MS disease pathogenesis, whether MS
symptoms promote the development of CVD and mor-
tality, or whether a shared underlying disturbance, such
as in glucose metabolism [56], underlies both disease
processes.
Treatment potential of ASA for cardiovascular
disease in patients with MS
ASA mechanisms of action
Aspirin (ASA) is a traditional nonsteroidal anti-
inflammatory drug (tNSAID) used to treat inflammation,
pain, and fever, and to inhibit platelet activation and aggre-
gation. This latter effect inhibits thrombus formation, thus
providing cardioprotection, and is the basis for the use of
ASA in the prevention of myocardial infarction [31, 57, 58].
The many therapeutic uses of ASA are due to its inhibition
of cyclooxygenases (COXs), enzymes that catalyze a step in
the production of prostanoids (Fig. 1). Prostanoids include
prostaglandins, prostacyclin, and thromboxanes, molecules
with pleiotropic effects on a large number of physiologic
systems [59].
A unique quality of ASA that differentiates it from
other tNSAIDs is its ability to covalently acetylate COXs
[60], whereas other tNSAIDS are competitive, reversible
inhibitors [59, 61]. The irreversible linkage by ASA inhibits
the enzyme’s ability to convert arachidonic acid to pros-
taglandin H2 (PGH2), a committed step in prostanoid
synthesis, and recovery of the system is directly related
to production of new COX enzymes. Cyclooxygenase-1
(COX-1) is considered to be constitutively expressed and
can be identified in most tissues [62]. Cyclooxygenase-2
(COX-2) is generally considered an inducible isozyme
Fig. 1 Aspirin inhibition of the synthetic pathway of prostaglandins I2, E2, and thromboxane A2. Cyclooxygenases metabolize arachidonic acid to
PGH2, which in turn is converted into various prostanoids by specific enzymes. Depending on the receptors activated by these molecules, mixed
physiologic effects on the vasculature and platelet reactivity occur. Aspirin irreversibly inhibits cyclooxygenase activity. COXs = cyclooxygenases;
PGH2 = prostaglandin H2; PGI synthase = prostaglandin-I synthase; PGE synthases = prostaglandin-E synthases; TXA synthase = thromboxane
synthase; PGI2 = prostacyclin; PGE2 = prostaglandin E2; TXA2 = thromboxane A2; IP receptor = prostacyclin receptor; EP receptors = prostaglandin
E2 receptors; TP receptors = thromboxane A2 receptors
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though it is also constitutively expressed in some cells
within the brain, testes, and kidney [62]. Therefore, COX-1
is thought to be the dominant source of prostanoids for
housekeeping functions and COX-2 is considered to be a
main source in inflammation, although platelet-derived
prostanoids generated through COX-1 are linked to pro-
motion of an inflammatory state [59, 63–65].
Once formed, PGH2 may be converted to prostaglandin
E2 (PGE2) by prostaglandin-E synthase; prostacyclin (PGI2)
by prostaglandin-I synthase; or thromboxane A2 (TXA2) by
thromboxane synthase [66, 67]. These mediators interact
with specific G-protein coupled receptors that utilize either
cAMP or IP3/DAG/Ca
2+ as second messengers ultimately
to elicit physiologic responses that often are in opposition
to each other. In terms of vascular smooth muscle tone
and platelet reactivity, PGI2 and TXA2 act conversely, with
PGI2 decreasing and TXA2 increasing these parameters
[64]. Also, PGI2 inhibits vascular smooth muscle cell prolifer-
ation and TXA2 promotes it [64]. Increases or decreases in
vascular tone and platelet reactivity can be elicited by PGE2,
depending on which of its five receptors are activated [64].Platelets participate in the thrombus formation process,
and as such, hyperactivity built upon underlying athero-
sclerosis can contribute to the development of pathological
cardiovascular events that may result in decreased blood
flow, acute coronary syndrome, and stroke [68, 69].
Through irreversible inhibition of platelet COX-1, and the
resultant decrease in TXA2 production, ASA decreases
platelet activation and aggregation, and demonstrates a car-
dioprotective effect [57, 64]. Inflammation plays a role in
the development of atherosclerotic plaques, and evidence
suggests that platelets contribute to inflammatory processes
through activation of vascular endothelial cells and leuko-
cytes in inflamed microvessels [70]. Furthermore, platelets
contain dense granules and α-granules that store preformed
chemical mediators. Upon platelet activation and subse-
quent degranulation, these mediators, which include
growth factors, cytokines, and coagulation factors, are re-
leased and can allow the platelet to influence the vascular
endothelium and the inflammatory response [70, 71]. In
neuroinflammatory disease states like MS, platelet activa-
tion could aggravate the disease process [65, 71–73]. In this
regard, ASA inhibition of platelet COX-1 could potentially
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tenuate the inflammatory state.
Since the COX inhibition by ASA is irreversible, the
antiplatelet effect is dependent on the synthesis of new
platelets. Therefore, lower doses of ASA (50–100 mg/
day) are effective due to action within platelets, thus
making it useful in the treatment of coronary artery
disease [31, 57, 58, 64, 74]. Distinct from this platelet ef-
fect, higher doses are used for analgesic, antipyretic, and
anti-inflammatory effects and are usually taken only as
needed as opposed to daily [59].
ASA use in preventing cardiovascular disease
In order to assess the potential impact of ASA to coun-
ter cardiovascular events in MS, it is helpful to address
its role in reducing CVD in other segments of the popu-
lation. In the general population, regular ASA use for
prevention of cardiovascular events ranges between 18–
41 %, and usage can be more prevalent in subpopula-
tions, for example, diabetics and older individuals who
are at higher risk for CVD [75–78]. Long-term adminis-
tration of ASA at low doses helps prevent strokes, heart
attacks, and blood clot formation in people at high risk
of these events [24–26]. In an analysis of antiplatelet
treatment following acute ischemic stroke, Sandercock
et al. [79] found a significant decrease in recurrent ische-
mic stroke and death in patients who began ASA treat-
ment no more than 14 days following a presumed
ischemic stroke occurrence (OR 0.95, 95 % CI 0.91–
0.99). It has also been noted that although there is a
slight increase in the incidence of intracranial hemor-
rhages with antiplatelet treatment, the benefits of pre-
venting repeat ischemic strokes and other cardiovascular
events such as pulmonary embolism (PE) outweigh the
risks of intracranial bleeding [30, 79]. ASA monotherapy
(50–325 mg/day), clopidogrel, or extended-release dipyr-
idamole (ER-DP) combined with ASA are therapies rec-
ommended by the American Heart Association and
American Stroke Association, as well as the Eighth
American College of Chest Physicians (ACCP), for the
secondary prevention of ischemic strokes in individuals
with a history of ischemic events including stroke [25,
80, 81]. The combination of ASA and ER-DP is prefera-
ble to ASA alone, while the combination of ASA with
clopidogrel has a heightened risk of bleeding events, and
thus should be avoided [25, 26, 80–83].
Although ASA has been established as effective for
preventing secondary cerebrovascular events [26], its
prophylactic efficacy is less clear. A significant reduction
in the risks for a first myocardial infarction was found
with ASA usage, but results for ASA’s efficacy in pre-
venting a first stroke and CVD were inconclusive [31,
84]. A review of 27 studies on the effectiveness of ASA
for the primary prevention of cardiovascular events (forexample, in patients not at risk for CVD) revealed only
modest/minor benefits that did not outweigh the risks of
increased bleeding and hemorrhagic strokes [32].
Platelets were traditionally considered to play a greater
role in arterial rather than venous thrombosis, but platelets
have been shown to have a role in venous thromboembol-
ism (VTE) by inducing the formation of neutrophil extra-
cellular traps, releasing proinflammatory mediators and
microparticles, and aggregating as a component of thrombi
themselves [27]. While some studies such as the Longitu-
dinal Investigation on Thromboembolism Etiology did not
find a reduction in VTE by ASA users [85], other trials re-
port that ASA lowers the risk of deep vein thrombosis
(DVT) [29]. The INSPIRE study combined data from two
previous studies where patients were given ASA after a first
unprovoked VTE to determine its effects on VTE recur-
rence. The INSPIRE analysis found that ASA reduces the
overall risk of recurrent VTE by 42 % (P = 0.005) with only
minor bleeding concerns, supporting the use of ASA for
secondary prophylaxis of VTE [28]. In the large Pulmonary
Embolism Prevention (PEP) trial, which included over
13,000 patients undergoing surgery for hip fracture or elect-
ive arthroplasty, PE or DVT was experienced in 105 out of
6,679 (1.5 %) patients receiving 160 mg ASA compared to
165 of 6,677 (2.5 %) patients receiving a placebo, which
equals a proportional reduction of 36 % PE/DVT in those
treated with ASA (P = 0.0003) [86]. ASA was also found to
be effective for the prevention of PE in high-risk patients by
the Antithrombotic Trialists’ Collaboration in a 2002 meta-
analysis: patients taking an antiplatelet (for example, ASA)
had a 25 % reduced risk of acute PE compared with pa-
tients on placebo (P < 0.01) [87]. Based on results such as
these and the low cost and relatively low risk of bleeding of
ASA when compared to warfarin and newer anticoagulants,
the American Academy of Orthopedic Surgeons in 2009
and the ACCP in 2012 included ASA as a method in their
guidelines to prevent VTE in high-risk orthopedic surgery
patients [27, 88].
Considerations regarding ASA use for cardiovascular
disease in patients with MS
Given that ASA may reduce cardiovascular events in
non-MS patients at risk, the possible elevated risks for
stroke and venous thrombosis in MS, along with the ob-
servance of vessel congestion [14, 89–91] and altered
perfusion of cerebral structures [9–12, 92] in this popu-
lation, suggests that MS patients taking ASA may have
some degree of protection against stroke or venous
thrombosis (Table 1). However, the slight risk of in-
creased intracerebral bleeding observed in stroke pa-
tients given ASA [79] is troubling, since MS patients
have a compromised BBB [7, 8] and ASA treatment
could further disrupt the BBB (Table 2). For example,
the elevated coagulation proteins observed in the CNS
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ive role by limiting BBB leakage, and if ASA disrupted
their deposition, then this could slow the resolution of
the leakage. However, ASA can act to limit vascular leak-
age: ASA reduced arachidonate-induced vascular leakage
in the peritoneum [93] and induced lipoxin A4, which
was found to reduce vascular leakage following acute ear
inflammation [94]. ASA also lowered the permeability of
the BBB in non-stroke patients [95].
It might be important to identify patients with MS
who have a heightened risk of a cardiovascular event, as
they would be expected to have the most favorable risk-
to-benefit ratio when using ASA. Besides the traditional
risk factors for cardiovascular events, there are features
of MS that may potentially lead to increased risk of
CVD within the MS population. For example, a more
sedentary or immobile state in MS patients [42, 44] or
taking an MS DMT [46–49] might be associated with an
increased risk of cardiovascular events.
ASA and antiphospholipid antibodies
Multiple studies have reported that APLAs are more
prevalent in patients with MS than in the general popu-
lation [96–98]. APLAs are the main diagnostic feature of
APS, an autoimmune disease characterized by throm-
bosis and/or pregnancy morbidity and elevated levels of
anticardiolipin antibodies, lupus anticoagulant, and/or β2
glycoprotein I [99]. MS and APS share various features,
and one disorder can sometimes be misdiagnosed for
the other [96, 99]. Although the role that APLAs may
have in MS is presently unclear, recent studies indicate a
relationship between APLAs and a more severe MS
disease course [97, 98, 100–102]. In a prospective three-
year study following interferon-β (INF-β)-treated MS pa-
tients with or without APLAs, Zivanidov et al. found
that the APLA-positive patients showed a greater disease
progression as measured by higher MRI lesion volumes,
increased tissue damage, and loss of brain volume, as
well as more clinical relapses [102]. The presence of
anti-INF-β binding antibodies may decrease the efficacy
of INF-β treatment, and Garg et al. [103] found a signifi-
cant co-occurrence of high APLAs in MS patients with
anti-INF-β binding antibodies. A higher frequency of
APLAs has been reported in secondary progressive MS
(SPMS) compared to RRMS, which is consistent with
the idea that the presence of APLAs is related to a more
chronic, advanced stage of the disease [97, 102, 104].
Given that thromboses are a main symptom in APS,
anticoagulation, antiaggregation, and ASA are all used as
treatment for this syndrome [96, 99, 102]. Although
many physicians prescribe daily low-dose ASA for
asymptomatic APLA-positive patients to prevent a first
thrombotic event, results from studies on the benefit of
ASA prophylaxis in this population are mixed [105]. TheAntiphospholipid Antibody Acetylsalicylic Acid study
found that 81 mg of ASA daily for APLA-positive but
asymptomatic patients was not more effective than pla-
cebo in protecting against a thrombotic event [106]. In
contrast, in an individual patient-level meta-analysis
from five international cohort studies, Arnaud and col-
leagues [107] found that prophylactic low-dose ASA in
patients with APLAs significantly reduced the risk of a
first thrombotic event. Although the role of APLAs in
the pathogenesis of MS is not clear, given that MS is as-
sociated with an increased risk of thrombosis and car-
diovascular events (see, for example, [18, 20, 21]), MS
patients with APLAs may benefit from anticoagulation
or ASA treatment.
Potential effects of ASA on vascular pathology in MS
In addition to affecting thrombosis and stroke in MS pa-
tients, ASA could affect other components of vascular
pathology in MS. Pathological changes to the vascular
tissue in the CNS have been observed since the earliest
descriptions of MS (see, for example, [89, 108]), and they
include platelet and fibrin deposits associated with ves-
sels in active lesions, vessel occlusion, vascular thicken-
ing, enhanced deposition of perivascular collagen, BBB
disruption, and perivascular inflammation [7, 8, 14–16,
109]. Proteomic analysis revealed the deposition of an
array of coagulation proteins in chronic active plaques
[110], and anticoagulants decreased the severity of ex-
perimental autoimmune encephalomyelitis (EAE) [110],
an animal model of MS, indicating that vascular changes
have a detrimental role in the disease.
Platelets are activated in MS and have been implicated
in contributing to pathogenesis, for example, by promot-
ing inflammation [65, 71–73]. Platelets were identified in
MS and EAE CNS lesions, and depletion of platelets
lessened EAE severity [73]. Two indicators of platelet ac-
tivation, β-thromboglobulin (β-TG) and platelet factor 4
(PF4), were higher in the plasma of MS patients during
quiescent disease compared to control subjects (P <
0.001) [111]. ASA 50 mg/day taken orally by patients
with MS significantly lowered plasma β-TG levels (P <
0.001), but not to normal levels [111]. PF4 levels did not
undergo a significant decline following ASA treatment,
suggesting that a source other than platelets, for ex-
ample, mast cells, could have been an important con-
tributor to PF4 levels in the plasma of these patients
[111]. In normal male subjects, ASA decreased platelet ag-
gregation and P-selectin expression in a dose-dependent
manner, and low ASA doses increased the dilatation of
the brachial artery while high doses decreased flow [112].
Although these studies suggest a benefit of ASA by inhi-
biting platelet activation, more studies are needed to
confirm the results and elucidate the specific mechanism
of action.
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EAE [73], fibrin deposition has been credited with acti-
vation of microglia, which have been associated with tis-
sue damage [113]. Depending on the type, microglia can
have different influences on disease activity in MS; that
is, they can induce tissue damage or promote repair [5].
Blockage of fibrin formation lessened disease activity in
EAE [114, 115]. ASA may promote fibrinolysis or inter-
fere with fibrin deposition [116].
In addition to fibrin, thrombin activity has been asso-
ciated with worsening of inflammatory CNS disease
states such as MS [117], and thrombin activity in the
spinal cord of mice with EAE is associated with multiple
pathological features [118]. ASA may decrease thrombin
levels at sites of microvascular injury [119]. In experi-
mental APS, which models a condition that results in
clots in deep veins and in organs such as the brain, ASA
also reduced tumor necrosis factor alpha (TNFα) and
prostaglandin E synthesis and increased thrombin inhibi-
tors [120].
Vascular changes may contribute to the decreased per-
fusion observed in MS [9–12, 92, 121]. Decreased perfu-
sion has been observed in the cortex [9, 10, 12], deep
gray matter structures (for example, thalamus, caudate)
[10–12], and normal-appearing white matter (NAWM)
[92] of patients with MS. In addition, white matter le-
sions from patients with RRMS had altered perfusion
(some with decreased perfusion and others with an in-
creased perfusion compared to that from white matter
in control subjects) [10, 122]. The extent of white matter
lesions was correlated with decreased cortical blood flow
[123], and decreased cerebral blood flow has also been
observed in EAE [124, 125].
Decreased perfusion could impair tissue oxygenation.
Decreased tissue oxygenation in MS patients has been
detected in white matter and cortex gray matter by
positron emission tomography [126], and decreased
utilization of oxygen in MS was revealed in periventricu-
lar veins by susceptibility-weighted imaging (SWI) [127]
and by T2-relaxation-under-spin-tagging of venous sinus
blood [128]. Additionally, lesions observed by SWI in
the spinal cord of EAE mice were thought to be detected
largely due to deoxyhemoglobin, whose presence was
likely a result of hypoxia [129]. At the molecular level,
upregulation of hypoxia-inducible factor-1α (HIF-1α)
has been observed in active MS plaques by immunohis-
tochemistry [130, 131], and the upregulation of genes
associated with ischemic preconditioning, including
HIF-1α, has been observed in NAWM in patients with
MS [132]. Additionally, endoplasmic reticulum stress
proteins, which have been associated with ischemic in-
jury, are overexpressed in active MS lesions [133, 134]
and in gray matter MS lesions [135]. Although altered
perfusion may reduce oxygen delivery and impair energyproduction [136], vascular changes, that is, microvascu-
lar thrombosis, as the cause of hypoxia-like changes in
MS have been questioned, since hypoxia-like changes
have been observed in MS patients in the absence of
vascular pathology [137].
Mitochondrial dysfunction has been observed in mul-
tiple sites in the CNS of MS patients, including NAWM,
lesions, and cortex, and altered mitochondria function
may help create a hypoxic state [35, 137–139]. ASA may
act to inhibit complex I of the respiratory chain [33].
Complex I is decreased in chronic active white matter
lesions and in the motor cortex of patients with MS [34,
35]. Thus, ASA has the potential to further lower com-
plex I activity in MS, and ASA’s inhibitory effect may be
more pronounced with depletion of glutathione [140],
which is thought to occur in patients with MS [141,
142]. Furthermore, inhibition of complex I activity can
lead to an increased production of reactive oxygen spe-
cies (ROS) [143], which could amplify cellular damage.
Cerebrovascular reactivity, the ability of the cerebral
vasculature to increase local blood flow via arteriole dila-
tion in response to neural activity, is impaired in MS,
perhaps as a result of vascular desensitization from
chronic high levels of nitric oxide stemming from in-
flammation [144]. Interestingly, ASA has been found to
increase endothelial nitric oxide synthase activity [145,
146], which would favor an increase in blood flow, but
not if vascular desensitization has developed [144].
ASA effects on MS symptoms
ASA in MS, EAE, and related studies
The cardiovascular effects of ASA would not be ex-
pected to readily translate into gross alterations of MS
disease activity. Only a couple of studies have looked dir-
ectly at the effects of ASA on MS disease activity, and
they were performed decades ago using relatively elem-
entary outcome measures. Two studies in the early
1960s examined the effects of calcium aspirin (Solprin)
(3.5 g divided over 3 doses per day) against prednisolone
(15 mg once per day initially; reduced to 10 mg per day
at 8 months) and placebo (lactate tablets) [147], or
chloroquine (250 mg once per day) and placebo [148], in
MS. Each patient’s disease condition was measured using
Alexander’s 1958 numerical scoring system prior to
treatment and at 6 and 18 or 6 and 14 months following
treatment, respectively. No significant differences were
found between treatment groups in either study, al-
though patients receiving Solprin in the prednisolone
study deteriorated the least over 18 months [147], and
Solprin performed better than chloroquine but worse
than the placebo in the latter experiment [148]. Given
that these studies were conducted using an outdated
measure of MS disease activity, the interpretation of
the results should be viewed cautiously. MRI studies,
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flow, and other more current measures of MS disease
activity could provide greater insights regarding the ef-
fect of ASA on disease progression.
Studies examining ASA in animal models of MS also
have been relatively sparse. One study published in 1949
examined the prophylactic and therapeutic effects of so-
dium salicylate (the main metabolite of ASA) and para-
aminobenzoic acid, either alone or in combination, in a
guinea pig EAE model [149]. Although neither com-
pound showed effects against disease onset and progres-
sion at moderate dosage levels, the combination of
sodium salicylate and para-aminobenzoic acid, as well as
larger doses of sodium salicylate by itself, seemed to
delay onset, lessen incidence, and inhibit disease severity
if administration was begun prior to or shortly after (5
days or less) EAE induction [149]. Treatment with so-
dium salicylate or the combined drugs after the animals
became sick had no effect on the disease [149]. When
ASA was tested in the guinea pig EAE model by another
group, there was no beneficial effect [150]. In the Lewis
rat model of EAE, ASA delayed the onset of disease
but increased the severity of disease [151], while so-
dium salicylate postponed disease onset and reduced
clinical signs [152].
More recent studies have looked at the role of COX-1
and COX-2 in EAE. Naproxen, a COX-1 and COX-2 in-
hibitor, was shown to delay EAE onset and reduce the
severity of the disease when treatment was started on
the day of EAE immunization [153]. In another study,
celecoxib, a new generation COX-2 inhibitor, reduced
EAE incidence and/or severity when animals were
treated beginning on the day of EAE induction or 8 days
post-induction [154]. But celecoxib also reduced disease
severity in COX-2-deficient mice; and nimesulide, an-
other COX-2 inhibitor, did not affect disease develop-
ment or severity, which indicates that the mechanism of
action of celecoxib on EAE is not via the COX-2 path-
way [154].
ASA was found to limit the production of ROS and
proinflammatory cytokines (for example, TNFα and IL-
1β) by a microglial cell line treated with the activator
lipopolysaccharide [155, 156], and ASA limited proin-
flammatory cytokine production and microglial activa-
tion following middle cerebral arterial occlusion in the
rat [157]. Activated microglia can mediate tissue damage
in MS [3–5], and lessening their production of inflam-
matory mediators by ASA could have possible benefits.
Also, it may be that ASA could promote resolution of
inflammation in MS by inducing lipoxin A4 [158], which
is an anti-inflammatory mediator [159].
In salt-loaded, stroke-prone, spontaneously hyperten-
sive rats, ASA suppressed BBB damage and reduced
several markers of inflammation (for example, matrixmetalloproteinase-9 activity, superoxide production,
and macrophage accumulation) [160], raising the pos-
sibility that ASA could limit similar pathological pro-
cesses in MS.
Recent studies found that ASA upregulated the pro-
duction of the ciliary neurotrophic factor [161], which
augments myelin formation [162]. ASA also induced the
proliferation and differentiation of oligodendrocyte pre-
cursors and limited demyelination following a cerebral
ischemic lesion [163]. If ASA acted similarly in response
to MS lesions, then it could promote remyelination ef-
forts [161].
ASA and fatigue
Fatigue is a pervasive and debilitating symptom associ-
ated with a marked decrease in the quality of life for pa-
tients with MS. The cause of fatigue is not understood.
Some possible theories concerning the causes of fatigue
have included: elevated body temperature (in RRMS pa-
tients) [164], sleep disturbances and depression [165,
166], proinflammatory cytokines [167], reduced metabol-
ism and degeneration of cerebral and deep gray matter
structures [168, 169], reduced connectivity [170], and re-
duced perfusion of deep gray matter [11]. There are a
limited number of approaches used to counter fatigue in
MS, for example, amantadine, modafinil, vitamin D ana-
log, treatment for sleep disorder, and exercise [171–175].
Overall, studies have been conflicting as to the benefits
of these modalities, and better management of fatigue is
sorely needed.
ASA has been tested as a way to counter fatigue
(Table 1). Following observations in a clinical setting
that some MS patients seemed to experience a lessening
of fatigue while taking ASA for non-MS-related symp-
toms, a double-blind, randomized, crossover study of
650 mg oral ASA twice daily or placebo for 6 weeks was
initiated, where a modest but detectable improvement
was found during the treatment phase with ASA [176].
The mean obtained from the Modified Fatigue Impact
Scale (MFIS, range 0–84), which was administered
weekly, decreased from 46.3 ± 16.0 at baseline to 38.1 ±
17.0 during ASA administration versus 42.5 ± 18.8 dur-
ing placebo (ASA versus placebo, P = 0.043) [176]. In
addition, of the patients completing the crossover com-
ponents of the study, only 1/26 patients preferred pla-
cebo compared to 10/26 of patients preferring ASA
treatment (P = 0.012) when responding to the Global Fa-
tigue Change self-assessment [176]. None of the other
outcome measures for fatigue assessment revealed statis-
tically significant differences (10-point Visual Analog
Scale, Fatigue Severity Scale [FSS], MS-Specific Fatigue
Scale), but there was a trend towards a greater reduction
of fatigue symptoms while taking ASA on the Visual
Analog Scale (ASA versus placebo, P = 0.076) [176].
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ical trial for 52 patients with MS was conducted over a
ten-week period to study the effectiveness of ASA and
amantadine for alleviating fatigue in MS. Half of the pa-
tients were randomly assigned to receive 500 mg ASA
orally once daily for the first four weeks, and following a
two-week washout period were switched to 100 mg
amantadine orally twice a day for the final four weeks;
the other half of the patients received the treatments in
reverse order [177]. A significant decrease in self-
reported fatigue levels measured using the FSS with both
ASA and amantadine was found following a baseline
measurement [177]. After the first round of treatment,
mean FSS scores decreased by 1.1 (from a maximum of
7) for ASA and by 0.8 for amantadine [177]. During the
two-week washout period, the mean FSS scores in-
creased back to baseline levels [177]. In the second
phase of the study, where patients received crossover
treatments, self-reported fatigue scores were once again
reduced significantly for each treatment regimen: mean
FSS decreased by 0.7 for ASA and by 1.6 for amantadine
[177]. The authors noted that both ASA and amantadine
were well-tolerated by patients with few and mild side
effects, none of which led to participant dropouts. Given
the promising results shown by both treatments in these
studies, they suggest that ASA and amantadine deserve
further consideration as potential treatments to combat
fatigue in MS [177].
A placebo-controlled, double-blind, multicenter study
was performed comparing placebo, 162 mg/d and 1,300
mg/d of ASA [178]. Although the study was not com-
pleted, an intermediate analysis of the placebo and high
dose groups revealed a difference of 4.6 points on the
MFIS, that is, adjusted mean scores of 42.7 versus 38.1
in the respective groups. However, the study was under-
powered and it did not reveal a statistically significant
effect [178]. The authors indicated that it is unlikely that
ASA provides a clinically relevant benefit for MS pa-
tients [178]. It is possible that confounding factors, such
as an undiagnosed sleep disorder [166], could interfere
with ASA effect on fatigue.
The mechanism of action by which ASA might lessen
fatigue, even minimally, is unclear. ASA’s reduction of
fatigue symptoms may be through the drug’s antipyretic
effects [176, 177], which is supported by a recent study
that found a correlation between fatigue, as measured by
FSS and MFIS, and elevated body temperature in RRMS
patients [164]. In addition, ASA could have affected
other systems (for example, autonomic or neuroendo-
crine) involved in the perception of fatigue [176, 177].
ASA also could have countered proinflammatory cyto-
kines [176, 177], which may contribute to fatigue [167,
179]. ASA may also act on fatigue associated with some
form of interferon-β therapy, which was taken by 5/30patients in the Wingerchuck et al. (2005) study [176]
and by 52/52 patients in the Shaygannejad et al. (2012)
study [177].
ASA and depression
Patients with MS are more likely to experience depres-
sion than the general population [180]. Although
depression has traditionally been thought of as a
neurotransmitter-related/driven disease, evidence sug-
gests that inflammation may play a role in the disorder
[181]. As such, drugs that reduce inflammation may
be beneficial in depression [181].
The use of ASA may lower the risk of major depres-
sion [182]. A study on depression and anxiety in patients
with myocardial infarction found that those taking ASA
reported fewer depression and anxiety symptoms (P <
0.01) as measured by the Hamilton Depression and
Hamilton Anxiety Rating Scales, respectively [183];
and an analysis of 174 male coronary angiography pa-
tients (99 on ASA) found fewer depressive symptoms
in those taking ASA regularly (range from 80 mg every
other day to 325 mg daily), both by self-report (P =
0.016) and reported perceptions from a significant
other (P = 0.048) [184].
In an established rodent model of depression, ASA
lessened immobility in a forced swim test in rats and
concurrently attenuated cytokine levels (IL-6 and TNF-
α) [185]. Additionally, preliminary clinical trials have re-
ported that ASA in combination with antidepressants
(fluoxetine) can shorten the onset of antidepressant ac-
tion and be effective against treatment-resistant depres-
sion [186], and this effect has also been demonstrated in
rats [187, 188]. However, 8 participants in a small clin-
ical sample (10 total) of patients experiencing depression
who were treated with 160 mg/day ASA in combination
with 20 mg/day of the antidepressant citalopram experi-
enced severe side effects (anxiety and akathesia) that ne-
cessitated the hospitalization of 4 participants while 2
other patients exhibited suicidal behavior, resulting in
the termination of the study at 14 days [189]. As such,
the authors caution the use of ASA in combination with
certain antidepressants such as citalopram [189]. Fur-
thermore, NSAIDs such as ibuprofen and ASA may
interfere with the antidepressant effects of selective
serotonin reuptake inhibitors (SSRIs) [190]. It has also
been found that the combined treatment of ASA with
an antidepressant (SSRI) increases the risk of bleeding
over ASA alone in patients who had experienced an
acute myocardial infarction [191]. Because damage of
the BBB [7, 8] and microhemorrhages [192–195] occur
in MS, caution is warranted when adding ASA to the
treatment regimen for MS patients who may be con-
currently receiving antidepressant treatment for de-
pressive symptoms.
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Due to the known pleiotropic effects of the prostaglan-
dins and thromboxanes on multiple physiological sys-
tems, it is not unexpected that inhibition of their
production by ASA could potentially cause various ad-
verse effects. Many of the major adverse effects related
to ASA use are discussed below and summarized in
Table 2.
While the incidence of cerebral hemorrhage during
ASA treatment is low in most studies, the antiplatelet ef-
fect of ASA can contribute to the development of in-
creased cerebral bleeding [30]. The Antithrombotic
Trialists’ Collaboration performed a meta-analysis (6 pri-
mary prevention trials and 16 secondary prevention tri-
als) of serious vascular events, including stroke and
major bleeds comparing long-term ASA versus control
[31]. Their conclusions included that ASA increased
incidences of hemorrhagic stroke in both primary (P =
0.05) and secondary (P = 0.07) prevention trials and
when analyzed in combination (P = 0.01), while ASA
showed a protective effect concerning ischemic stroke (P
= 0.005) [31]. Sutcliffe et al. [32] reviewed data from ran-
domized trials assessing ASA in the primary prevention
of CVD and cancer and concluded that the benefits of
ASA for primary prevention of CVD are modest, and are
much less than those for secondary prevention. Further-
more, while benefits and harms were low based on person-
years, they estimated an increased risk of hemorrhagic
stroke ranging from 32–38 % [32].
Although the increases in incidents of hemorrhagic
stroke noted are slight, it is possible that in disease states
like MS, where the BBB is disrupted or compromised [7,
8], the risk of intracerebral bleeding may be greater with
ASA usage. Additionally, there is an increased risk of
immune thrombocytopenia in patients with MS [196],
which would be a counter indication of ASA usage due
to the enhanced risk of bleeding with ASA in this pa-
tient population [197].
An adverse effect that is well associated with ASA use
is upper gastrointestinal (GI) tract injury and bleeding.
Because ASA inhibits the production of prostaglandins
by GI-located COX-1, these gastroprotective substances
are unavailable and damage may occur. The risk of com-
plications is increased with aging, concomitant use of
anticoagulants, history of NSAID-associated bleeding,
and comorbidities [198]. The Antithrombotic Trialists’
Collaboration study noted above determined that ASA
usage increased major GI and extracranial bleeds to 0.10 %
versus 0.07 % per year in controls (RR = 1.54 [1.30–1.82],
P < 0.0001) [31].
ASA and salicylate, the active metabolite of ASA, are
known to cause hearing loss and tinnitus at high doses
(for example, 6–8 g/day) [199–203]. The mechanisms
behind these effects are unclear, but salicylate seems tohave effects centrally on GABAergic neurotransmission
[203, 204], as well as more peripherally by affecting
cochlear function [200, 204]. Moreover, a strong linear
relationship exists between unbound salicylate plasma
concentration and a resultant decrease in auditory sensi-
tivity [205], and the salicylate toxicity model is used by
auditory scientists to investigate mechanisms underlying
tinnitus [204].
Certain asthmatic patients have a sensitivity to ASA
that manifests itself as a respiratory/asthma-type attack.
Jenkins et al. performed a systematic review and found
that the pooled incidence of ASA-induced asthma was
21 % in adults and 5 % in children [206]. This is higher
than the value of approximately 10 % that has been pub-
lished elsewhere [207, 208]. The mechanism of this reac-
tion in ASA sensitive-individuals is thought to occur due
to COX inhibition resulting in decreased PGE2 and thus
unabated activation of the 5-lipoxygenase pathway. This,
in turn, increases production of leukotrienes and mast
cell release of histamine, leading to airway hyperreactiv-
ity [209, 210].
Prostaglandin-mediated vasodilation is necessary for
proper renal plasma flow, especially in individuals with
underlying renal disease, congestive heart failure, or cir-
rhosis. Through inhibition of renal COX-2, ASA and
other NSAIDs can cause volume-dependent renal failure
and that resulting from interstitial nephritis and neph-
ritic syndrome [198].
Conclusion
Although ASA use is relatively common in the general
population, ASA usage by MS patients has the potential
for positive and/or negative influences on different facets
of the disease, that is, symptoms, disease mechanisms,
and associated disease risks. Understanding the impact
of ASA use on these features would help to further es-
tablish the risk-to-benefit ratio of ASA usage in this pa-
tient population. Venous thrombosis and possibly stroke
have an elevated likelihood in MS [17–23, 37], and given
that ASA can lessen the risks of these cerebrovascular
diseases [25, 26, 29], it is likely that ASA confers a simi-
lar benefit of lower risk for MS patients. Fatigue is a
relatively common symptom in MS, and ASA may
ameliorate fatigue in MS patients [176, 177], although
the effect size might be small [178]. ASA could also im-
pact pathogenic processes. For example, ASA could act
to reduce inflammation by limiting the production of
proinflammatory mediators from activated microglia
[155–157] or by inducing the production of lipoxin A4,
which acts to resolve inflammation [158, 159]. Since a
pathogenic role has been attributed to platelets and
thrombin [65, 71–73, 117, 118], lessening their activa-
tion by ASA could potentially reduce their ability to
stimulate inflammation or impair blood flow [112, 116,
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have negative side effects such as being associated with
an elevated risk of hemorrhagic stroke [30–32]. ASA
may also worsen some specific components of MS path-
ology, for example, enhancing leakage of the BBB and
possibly inhibiting mitochondrial complex I activity [33],
which is already reduced in MS [34, 35]. It is possible
that subgroups of MS patients may find particular bene-
fit from ASA, for example, immobile patients with in-
creased risk for DVTs or patients with APLAs, which
could counterbalance the risks associated with ASA
usage. It is also possible that ASA usage has a small
beneficial impact on overall disease progression. Thus,
further studies are needed to determine the benefits and
risks of ASA in patients with MS in order to establish proper
guidance for ASA use by this patient population. Given
the widespread usage of aspirin and the likelihood that
many effects could be small, traditional placebo controlled
trials would be unlikely to yield meaningful results. Carefully
crafted population-based studies, while not definitive, may
help guide our understanding of this complex issue.
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